Results 41 to 50 of about 2,710 (165)

Acute kidney injury and morbi‐mortality associated with “triple whammy” combination: Systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3031-3041, November 2025.
Aims “Triple whammy” (TW) refers to the concomitant use of diuretics, renin‐angiotensin‐aldosterone system inhibitors (RAASI) and non‐steroidal anti‐inflammatory drugs (NSAIDs). The aim of this article is to analyse the association between TW exposure and acute kidney injury (AKI), among other morbi‐mortality outcomes.
Dulce María Calvo, Luis Carlos Saiz, Leire Leache, Maria Concepción Celaya, Marta Gutiérrez‐Valencia   +4 more
wiley   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, Volume 27, Issue 11, Page 2198-2210, November 2025.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Therapeutics and Clinical Risk Management, 2011
Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class ...
Ali AK
doaj  

The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

PLoS ONE, 2013
BackgroundLaboratory research and previous study suggest that aliskiren, a direct renin inhibitor, has anti-proteinuric effects. We conducted a randomized crossover study to evaluate the anti-proteinuric effect of aliskiren in patients with ...
Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Chi-Bon Leung, Philip Kam-Tao Li   +4 more
doaj   +1 more source

Effects of Aliskiren, an RAAS inhibitor, on a carrageenan-induced pleurisy model of rats

Anais da Academia Brasileira de Ciências, 2018
Our aim is to investigate the potentially preventive effects of Aliskiren in a carrageenan-induced lung pleurisy model and to compare the standard anti-inflammatory agents, indomethacin and dexamethasone.
YASIN BAYIR, HARUN UN, ELIF CADIRCI, EROL AKPINAR, BUSRA DIYARBAKIR, ILKNUR CALIK, ZEKAI HALICI   +6 more
doaj   +1 more source

Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease

Journal of Diabetes, Volume 18, Issue 7, July 2026.
Zachary Bloomgarden
wiley   +1 more source

Advancing antihypertensive drug development

British Journal of Pharmacology, Volume 182, Issue 15, Page 3389-3410, August 2025.
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges.
Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang, Darren Green, Hongyuan Zhang   +5 more
wiley   +1 more source

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome

Diabetology & Metabolic Syndrome, 2017
Background Non-alcoholic steatohepatitis (NASH) is highly associated with metabolic syndrome, a major cause of morbidity in the globalized society. The renin–angiotensin system (RAS) influences hepatic fatty acid metabolism, inflammation and fibrosis ...
F. N. Ramalho, S. C. Sanches, M. C. Foss, M. J. Augusto, D. M. Silva, A. M. Oliveira, L. N. Ramalho   +6 more
doaj   +1 more source

Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE [PDF]

European Journal of Heart Failure, 2012
Blockade of the renin–angiotensin system (RAS) is a core therapeutic strategy in systolic heart failure.1 The value of angiotensin-converting enzyme (ACE) inhibitors was proven in two pivotal trials conducted >20 years ago. More recently, angiotensin receptor blockers (ARBs) have also been shown to be beneficial in systolic heart failure both as an ...
McMurray, John J V, Abraham, William T, Dickstein, Kenneth, Køber, Lars, Massie, Barry M, Krum, Henry   +5 more
openaire   +3 more sources

Recent Advances in Nanomedicine‐Mediated Abdominal Aortic Aneurysm Treatment

Small Methods, Volume 9, Issue 7, July 19, 2025.
Bridge the gap. Emerging strategies such as nanoparticle platforms and cell therapies may help advance the medication management of abdominal aortic aneurysm from laboratory to clinical application. By enhancing the precision, efficacy, ad comprehensiveness of drug delivery, a wide range of studies have obtained positive outcomes and are summarized in ...
Xinchen Lu, Quanyin Hu
wiley   +1 more source